Table 1.
Associations of SIRT5 expression with clinicopathological variables in patients with gastric cancer (n = 176).
| No expression | Expression | ||
|---|---|---|---|
| Characteristic | (n = 112) | (n = 64) | P |
| Age | 65.89 | 67.88 | 0.38 |
| Tumor size (cm) | |||
| <4 | 40 | 28 | |
| 4–8 | 44 | 24 | |
| >8 | 28 | 12 | 0.49 |
| Tumor location | |||
| Upper stomach | 28 | 18 | |
| Middle stomach | 34 | 18 | |
| Lower stomach | 46 | 26 | |
| Whole stomach | 4 | 2 | 0.97 |
| Cell grade | |||
| Poorly differentiated | 90 | 40 | |
| Moderately differentiated | 20 | 22 | |
| Well-differentiated | 2 | 2 | 0.35 |
| Gross appearance | |||
| Superficial type | 30 | 16 | |
| Borrmann types I and II | 38 | 24 | |
| Borrmann types III and IV | 44 | 28 | 0.89 |
| Lauren’s histology | |||
| Intestinal type | 54 | 28 | |
| Diffuse type | 58 | 36 | 0.56 |
| Nodal involvement | |||
| Negative | 18 | 20 | |
| Positive | 94 | 44 | 0.02* |
| Lymphovascular invasion | |||
| No | 20 | 28 | |
| Yes | 92 | 36 | 0.0002* |
| Depth of cancer invasion | |||
| Mucosa | 10 | 4 | |
| Submucosa | 14 | 6 | |
| Proper muscle | 48 | 24 | |
| Serosa | 40 | 30 | 0.52 |
| TNM stage | |||
| I | 10 | 4 | |
| II | 70 | 38 | |
| III | 32 | 22 | 0.64 |
| 5-Year OS | 39.10% | 51.20% | 0.005* |
| 5-Year DFS | 38.00% | 49.60% | 0.010* |
*
P < 0.05.
SIRT5, sirtuin 5; OS, overall survival; DFS, disease-free survival.